FDA approves Ocular's Dextenza for post-surgery pain

FDA approved Dextenza sustained-release dexamethasone insert from Ocular Therapeutix Inc. (NASDAQ:OCUL) for intracanalicular use to treat ocular pain following ophthalmic surgery.

Ocular had received two complete response letters from FDA for Dextenza, the first in July 2016 and the second in July 2017 (see "FDA Reviewing Ocular's Dextenza for Third Time")...